DigestRedComo funciona
Red
/
Empresas
No
No verificado

Novo Nordisk A/S

Sobre qué escribimos

FarmacéuticaFinanzasGestión empresarial/Administración de EmpresasPolítica InternacionalPublicidad/Marketing/Medios de comunicación/Comunicación

81 Comunicados de prensa

Ver todos los comunicados de prensa
02/03/2026
Farmacéutica
Política Internacional
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
02/03/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
25/02/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Gestión empresarial/Administración de Empresas
Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
24/02/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
23/02/2026
Farmacéutica
Política Internacional
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
20/02/2026
Farmacéutica
Política Internacional
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
17/02/2026
Farmacéutica
Medicina Salud Bienestar
Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
05/02/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
04/02/2026
Farmacéutica
Finanzas
Novo Nordisk files annual report with the SEC
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
03/02/2026
Farmacéutica
Finanzas
Política Internacional
Novo Nordisk initiates 2026 share repurchase programme
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0